Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of One Dose of OVX836 Influenza Vaccine 480μg, After Intramuscular Administration in Healthy Subjects Aged 18-55 Years
Latest Information Update: 10 Oct 2022
Price :
$35 *
At a glance
- Drugs OVX-836 (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors OSIVAX
- 23 Jun 2022 According to an Osivax media release, the company received has secured EUR 10M from Bpifrance and the company will apply this funds to prepare OVX836 for this study.
- 13 Jul 2020 New trial record